S&P 500   4,657.22 (+1.36%)
DOW   35,139.35 (+0.69%)
QQQ   398.68 (+1.91%)
AAPL   160.38 (+2.28%)
MSFT   337.98 (+2.52%)
FB   337.64 (+1.36%)
GOOGL   2,901.19 (+2.02%)
AMZN   3,582.18 (+2.21%)
TSLA   1,132.99 (+4.72%)
NVDA   328.41 (+4.25%)
BABA   131.76 (-1.19%)
NIO   40.01 (+0.05%)
CGC   11.02 (-5.73%)
AMD   158.89 (+2.64%)
GE   97.51 (-0.34%)
MU   84.79 (+1.64%)
T   23.88 (-1.40%)
F   19.73 (-0.10%)
DIS   144.95 (-2.13%)
ACB   6.43 (-5.30%)
AMC   36.47 (-3.08%)
PFE   53.77 (-0.43%)
BA   196.50 (-1.36%)
S&P 500   4,657.22 (+1.36%)
DOW   35,139.35 (+0.69%)
QQQ   398.68 (+1.91%)
AAPL   160.38 (+2.28%)
MSFT   337.98 (+2.52%)
FB   337.64 (+1.36%)
GOOGL   2,901.19 (+2.02%)
AMZN   3,582.18 (+2.21%)
TSLA   1,132.99 (+4.72%)
NVDA   328.41 (+4.25%)
BABA   131.76 (-1.19%)
NIO   40.01 (+0.05%)
CGC   11.02 (-5.73%)
AMD   158.89 (+2.64%)
GE   97.51 (-0.34%)
MU   84.79 (+1.64%)
T   23.88 (-1.40%)
F   19.73 (-0.10%)
DIS   144.95 (-2.13%)
ACB   6.43 (-5.30%)
AMC   36.47 (-3.08%)
PFE   53.77 (-0.43%)
BA   196.50 (-1.36%)
S&P 500   4,657.22 (+1.36%)
DOW   35,139.35 (+0.69%)
QQQ   398.68 (+1.91%)
AAPL   160.38 (+2.28%)
MSFT   337.98 (+2.52%)
FB   337.64 (+1.36%)
GOOGL   2,901.19 (+2.02%)
AMZN   3,582.18 (+2.21%)
TSLA   1,132.99 (+4.72%)
NVDA   328.41 (+4.25%)
BABA   131.76 (-1.19%)
NIO   40.01 (+0.05%)
CGC   11.02 (-5.73%)
AMD   158.89 (+2.64%)
GE   97.51 (-0.34%)
MU   84.79 (+1.64%)
T   23.88 (-1.40%)
F   19.73 (-0.10%)
DIS   144.95 (-2.13%)
ACB   6.43 (-5.30%)
AMC   36.47 (-3.08%)
PFE   53.77 (-0.43%)
BA   196.50 (-1.36%)
S&P 500   4,657.22 (+1.36%)
DOW   35,139.35 (+0.69%)
QQQ   398.68 (+1.91%)
AAPL   160.38 (+2.28%)
MSFT   337.98 (+2.52%)
FB   337.64 (+1.36%)
GOOGL   2,901.19 (+2.02%)
AMZN   3,582.18 (+2.21%)
TSLA   1,132.99 (+4.72%)
NVDA   328.41 (+4.25%)
BABA   131.76 (-1.19%)
NIO   40.01 (+0.05%)
CGC   11.02 (-5.73%)
AMD   158.89 (+2.64%)
GE   97.51 (-0.34%)
MU   84.79 (+1.64%)
T   23.88 (-1.40%)
F   19.73 (-0.10%)
DIS   144.95 (-2.13%)
ACB   6.43 (-5.30%)
AMC   36.47 (-3.08%)
PFE   53.77 (-0.43%)
BA   196.50 (-1.36%)
NASDAQ:CDTX

Cidara Therapeutics Stock Forecast, Price & News

$1.46
-0.01 (-0.68%)
(As of 11/29/2021 11:57 AM ET)
Add
Compare
Today's Range
$1.42
$1.49
50-Day Range
$1.40
$2.35
52-Week Range
$1.31
$3.15
Volume
5,241 shs
Average Volume
619,215 shs
Market Capitalization
$97.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.12
30 days | 90 days | 365 days | Advanced Chart
Receive CDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Cidara Therapeutics logo

About Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Headlines

Should I Buy Cidara Therapeutics Inc (CDTX)?
October 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDTX
Fax
N/A
Employees
79
Year Founded
N/A

Sales & Book Value

Annual Sales
$12.07 million
Book Value
($0.02) per share

Profitability

Net Income
$-72.11 million
Net Margins
-106.76%
Pretax Margin
-102.65%

Debt

Price-To-Earnings

Miscellaneous

Free Float
61,331,000
Market Cap
$97.36 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

2.21 out of 5 stars

Medical Sector

358th out of 1,392 stocks

Biological Products, Except Diagnostic Industry

56th out of 201 stocks

Analyst Opinion: 3.8Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

Is Cidara Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" Cidara Therapeutics stock.
View analyst ratings for Cidara Therapeutics
or view top-rated stocks.

How has Cidara Therapeutics' stock price been impacted by Coronavirus?

Cidara Therapeutics' stock was trading at $2.48 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDTX shares have decreased by 41.1% and is now trading at $1.46.
View which stocks have been most impacted by COVID-19
.

When is Cidara Therapeutics' next earnings date?

Cidara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cidara Therapeutics
.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) posted its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.01. Cidara Therapeutics had a negative net margin of 106.76% and a negative trailing twelve-month return on equity of 722.37%.
View Cidara Therapeutics' earnings history
.

What price target have analysts set for CDTX?

2 brokerages have issued 12-month price targets for Cidara Therapeutics' shares. Their forecasts range from $6.25 to $8.00. On average, they expect Cidara Therapeutics' stock price to reach $7.13 in the next year. This suggests a possible upside of 388.0% from the stock's current price.
View analysts' price targets for Cidara Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the following people:

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BVF Inc. IL (9.65%), Altium Capital Management LP (2.57%), Renaissance Technologies LLC (2.26%), Stonepine Capital Management LLC (1.58%), Two Sigma Advisers LP (0.95%) and Geode Capital Management LLC (0.77%). Company insiders that own Cidara Therapeutics stock include James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian, Paul Daruwala, Preetam Shah and Timothy R Franson.
View institutional ownership trends for Cidara Therapeutics
.

Which institutional investors are selling Cidara Therapeutics stock?

CDTX stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Millennium Management LLC, BlackRock Inc., Squarepoint Ops LLC, and Goldman Sachs Group Inc.. Company insiders that have sold Cidara Therapeutics company stock in the last year include Jessica Oien, Neil Abdollahian, and Paul Daruwala.
View insider buying and selling activity for Cidara Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Cidara Therapeutics stock?

CDTX stock was acquired by a variety of institutional investors in the last quarter, including Altium Capital Management LP, BVF Inc. IL, Two Sigma Advisers LP, Monashee Investment Management LLC, Two Sigma Investments LP, Marshall Wace LLP, Renaissance Technologies LLC, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Cidara Therapeutics stock in the last two years include James E Levine, Jeffrey Stein, Preetam Shah, and Timothy R Franson.
View insider buying and selling activity for Cidara Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $1.46.

How much money does Cidara Therapeutics make?

Cidara Therapeutics has a market capitalization of $97.36 million and generates $12.07 million in revenue each year. The biotechnology company earns $-72.11 million in net income (profit) each year or ($1.07) on an earnings per share basis.

How many employees does Cidara Therapeutics have?

Cidara Therapeutics employs 79 workers across the globe.

What is Cidara Therapeutics' official website?

The official website for Cidara Therapeutics is www.cidara.com.

Where are Cidara Therapeutics' headquarters?

Cidara Therapeutics is headquartered at 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 752-6170 or via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.